# reload+after+2024-01-20 06:44:24.721245
address1§161 Oyster Point Boulevard
city§South San Francisco
state§CA
zip§94080
country§United States
phone§650-866-8548
website§https://www.denalitherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Denali Therapeutics Inc., a biopharmaceutical company, developing a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases. It pursues new treatments by assessing genetically validated targets, engineering delivery across the blood-brain barrier, and guiding development through biomarkers that demonstrate target and pathway engagement. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; and DNL343 eIF2B Activator program for amyotrophic lateral sclerosis. The company's other programs comprise SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
fullTimeEmployees§447
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Ryan J. Watts Ph.D.', 'age': 47, 'title': 'Co-Founder, President, CEO & Director', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 1044200, 'exercisedValue': 2166082, 'unexercisedValue': 24372184}, {'maxAge': 1, 'name': 'Dr. Alexander O. Schuth M.D.', 'age': 50, 'title': 'Co-Founder, CFO, COO & Secretary', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 737200, 'exercisedValue': 601400, 'unexercisedValue': 8662979}, {'maxAge': 1, 'name': 'Dr. Marc  Tessier-Lavigne Ph.D.', 'age': 63, 'title': 'Co-Founder, Chairman of Scientific Advisory Board & Independent Director', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 58231, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Carole  Ho M.D.', 'age': 50, 'title': 'Chief Medical Officer & Head of Development', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 737200, 'exercisedValue': 0, 'unexercisedValue': 6147877}, {'maxAge': 1, 'name': 'Mr. Tyler M. Nielsen', 'age': 45, 'title': 'Senior Vice President of Corporate Finance', 'yearBorn': 1978, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Dana  Andersen', 'title': 'Chief Technical and Manufacturing Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Joe  Lewcock Ph.D.', 'title': 'Chief Scientific Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Laura  Hansen', 'title': 'Vice President of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Chris  Walsh', 'title': 'General Counsel', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mark  Rowen', 'title': 'Vice President of Corporate Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§1
boardRisk§4
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§6
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.239
priceToSalesTrailing12Months§7.8421946
currency§USD
dateShortInterest§1702598400
forwardEps§-2.98
exchange§NMS
quoteType§EQUITY
shortName§Denali Therapeutics Inc.
longName§Denali Therapeutics Inc.
firstTradeDateEpochUtc§1512743400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§8e41e38b-ee3c-33f3-b430-d43094ba2e88
gmtOffSetMilliseconds§-18000000
targetHighPrice§105.0
targetLowPrice§26.0
targetMeanPrice§47.19
targetMedianPrice§39.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§16
quickRatio§15.613
grossMargins§-0.19767
ebitdaMargins§-0.44256002
trailingPegRatio§None
